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Abstract
Autosomal recessive mutations in the thymidine kinase 2 gene
(TK2) cause mitochondrial DNA depletion, multiple deletions, or
both due to loss of TK2 enzyme activity and ensuing unbalanced
deoxynucleotide triphosphate (dNTP) pools. To bypass Tk2 defi-
ciency, we administered deoxycytidine and deoxythymidine mono-
phosphates (dCMP+dTMP) to the Tk2 H126N (Tk2/) knock-in
mouse model from postnatal day 4, when mutant mice are pheno-
typically normal, but biochemically affected. Assessment of
13-day-old Tk2/ mice treated with dCMP+dTMP 200 mg/kg/day
each (Tk2/200dCMP/dTMP) demonstrated that in mutant animals,
the compounds raise dTTP concentrations, increase levels of
mtDNA, ameliorate defects of mitochondrial respiratory chain
enzymes, and significantly prolong their lifespan (34 days with
treatment versus 13 days untreated). A second trial of
dCMP+dTMP each at 400 mg/kg/day showed even greater pheno-
typic and biochemical improvements. In conclusion, dCMP/dTMP
supplementation is the first effective pharmacologic treatment for
Tk2 deficiency.
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Introduction
Encoded by the nuclear DNA gene TK2, thymidine kinase 2 (TK2) is
a mitochondrial matrix protein that phosphorylates thymidine and
deoxycytidine pyrimidine nucleosides to generate deoxythymidine
monophosphate (dTMP) and deoxycytidine monophosphate (dCMP),
which, in turn, are converted to deoxynucleotide triphosphates
(dNTPs) required for mitochondrial DNA (mtDNA) synthesis.
Autosomal recessive TK2 mutations cause severe mtDNA depletion
and devastating neuromuscular diseases in infants and children, as
well as mtDNA multiple deletions and progressive external
ophthalmoplegia in adults (Saada et al, 2001; Tyynismaa et al,
2012).
To elucidate the molecular pathogenesis of TK2 deficiency, we
generated a homozygous Tk2 H126N knock-in mutant (Tk2/)
mouse that manifests a phenotype strikingly similar to the human
infantile encephalomyopathy (Akman et al, 2008). Between postna-
tal day 10 and 13, Tk2/ mice rapidly develop fatal encephalomy-
opathy beginning with decreased ambulation, unstable gait, coarse
tremor, and growth retardation that rapidly progress to early death
at age 14–16 days (Dorado et al, 2011). A similar phenotype was
observed in the Tk2 knockout mouse (Zhou et al, 2008).
In the Tk2/ mice, loss of Tk2 activity caused dNTP pool imbal-
ances with low dTTP levels in brain and decreased dTTP and dCTP
in liver, which, in turn, produce mtDNA depletion and defects of
mitochondrial respiratory chain (RC) complexes I, III, IV, and V
containing mtDNA-encoded subunits, most prominently in the brain
and spinal cord (Dorado et al, 2011).
Based on the understanding of the pathogenesis of Tk2 defi-
ciency, we have assessed a rationale therapeutic strategy to
bypass the enzymatic defect with oral dCMP and dTMP supple-
mentation.
Results
dCMP/dTMP delays disease onset, prevents neuromuscular
manifestations, and prolongs lifespan of Tk2-deficient mice
Oral treatment with dCMP+dTMP 200 mg/kg/day each in milk
(Tk2/200dCMP/dTMP) beginning at postnatal day 4 delayed disease
onset to 20–25 days (Supplementary Video S1), when the mutant
mice developed a mild tremor and stopped gaining weight. In the
fourth week, they manifested weakness and reduced movements. In
contrast, Tk2/ mice treated from day 4 with dCMP+dTMP
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400 mg/kg/day each in milk (Tk2/400dCMP/dTMP) appeared normal
until day 21, when weight gain decelerated and mild head tremor
developed (Fig 1A). Untreated Tk2/ mice had a mean lifespan of
13.2  2.5 days (mean  SD), whereas Tk2/200dCMP/dTMP
survived to 34.6  3.2 days (P = 0.0028; n = 7; Gehan–Breslow–
Wilcoxon test) while Tk2/400dCMP/dTMP lived to 44.3  9.1 days
(P = 0.0071; n = 7; Gehan–Breslow–Wilcoxon test) (Fig 1B). The
cause of death was not evident in postmortem histological studies of
major organs in 29-day-old Tk2/200dCMP/dTMP mice. No adverse
side effects, including malignancies, were observed in the treated
homozygous, and heterozygous wild types (Tk2+) and mutants
except mild deceleration of weight gain in Tk2+400dCMP/dTMP (Sup-
plementary Table S1).
Open-field assessment of motor function in 29-day-old
Tk2/200dCMP/dTMP, Tk2/400dCMP/dTMP, and wild-type Tk2 mice
showed no differences in the distance traveled, horizontal and
vertical movements, or resting time (Fig 1C–E). Relative to
29-day-old Tk2+ mice, age-matched Tk2/200dCMP/dTMP and
Tk2/400dCMP/dTMP animals showed decreases in gross muscle
mass and muscle fiber diameter that were independent of the treat-
ment dose but paralleled to body weight (Supplementary Fig S1).
Histology showed no signs of myopathy or mitochondrial abnor-
malities (Supplementary Fig S1A–D). Biochemical studies demon-
strated normal mitochondrial RC activities and protein levels
(Supplementary Fig S1D–F).
Histological and histochemical CNS studies confirmed dCMP/
dTMP efficacy
Efficacy of treatment in central nervous system (CNS) was demon-
strated in histological studies that showed dramatic reductions in
the numbers of vacuoles in neurons of the spinal cord and cerebellar
and brain stem nuclei of 13-day-old Tk2/200dCMP/dTMP mice rela-
tive to untreated 13-day-old Tk2/mice (Fig 2A and B). Further-
more, cytochrome c oxidase (COX, complex IV) histochemistry of
cerebellum revealed reduced overall COX activity in 13-day-old
untreated Tk2/mice (Fig 3A) with normal activities in 13- and
29-day-old Tk2/200dCMP/dTMP (Fig 3C and E) relative to Tk2+
animals (Fig 3B, D and F). No cell-specific immunohistochemical
differences in COX protein were detected (Fig 3G and H) while
severe reduction in complex I was identified by immunostaining of
cerebellum of 29-day-old Tk2/200dCMP/dTMP (Fig 3I and J).
Treatment crosses biological barriers
To confirm that the treatment crosses biological barriers, we
assessed dNTP levels in isolated mitochondria. In 13-day-old
untreated Tk2/ mice relative to Tk2+ littermates, isolated brain
mitochondria showed decreased levels of dTTP (0.67  0.1 pmol/
mg-protein versus 2.52  1.0), while isolated liver mitochondria
revealed reduced dCTP levels (1.07  0.8 versus 2.9  1.0)
C D E
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Figure 1. dCMP/dTMP efficacy on clinical phenotype.
A, B Significant dose-related effects of the dCMP/dTMP on body weight (A) and survival (B) of mutant mice (n = 7 for each group)(Tk2/ versus Tk2/200dCMP/dTMP,
P < 0.005; Tk2/ versus Tk2/400dCMP/dTMP, P < 0.005; Gehan-Breslow-Wilcoxon test).
C–E Open-field test in 29-day-old treated mice showing no difference in average distance traveled (C), ambulatory and resting times (D), and horizontal (XY axes) and
vertical (Z-axis) movements (E) over 10 min in 29-day-old mutant and control mice treated with 200 mg/kg/day or 400 mg/kg/day of dCMP/dTMP (n = 5) (Data
expressed as mean  SD. Statistical analysis were performed on Tk2/200dCMP/dTMP versus Tk2+200dCMP/dTMP and Tk2/400dCMP/dTMP versus Tk2+400dCMP/dTMP).
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(Supplementary Table S2). The treatment crossed the blood–brain
barrier increasing the level of dTTP in isolated brain mitochondria
of 13-day-old Tk2+200dCMP/dTMP (3.55  1) and Tk2/200dCMP/dTMP
(1.5  0.7) and as a consequence, restored the proportion of dTTP
relative to total dNTP in treated mutants. In contrast, levels of dCTP
in isolated mitochondria were stable in brain of 13-day-old
Tk2+200dCMP/dTMP (3.07  2), decreased in brain of Tk2/200dCMP/dTMP
(1.13  0.5), and decreased in liver of 13-day-old Tk2+200dCMP/dTMP
(1.13  0.4) and Tk2/200dCMP/dTMP (0.56  0.5) (Supplementary
Table S2).
In 29-day-old Tk2/200dCMP/dTMP relative to Tk2+ mice, absolute
levels of dTTP and dCTP were markedly reduced in isolated mito-
chondria from brain (dTTP 0.11  0.05 and dCTP 0.6  0.2) and
from liver (dTTP 0.15  0.04 and dCTP 0.04  0.03) (Supplemen-
tary Table S2); when these data were expressed as percentage of
total dNTPs, there were striking decreases in dTTP/dNTP in brain
(P = 0.0322; n = 7; Mann–Whitney U-test) and dCTP/dNTP in liver
(P = 0.0338; n = 3; Mann–Whitney U-test) (Fig 4A and B).
dCMP/dTMP treatment ameliorates biochemical and molecular
genetic abnormalities
Treatment with dCMP and dTMP enhanced mtDNA levels in the
mutant mice. At pre-treatment baseline, 4-day-old Tk2/ mice did
not manifest clinical abnormalities, but showed reductions of mtDNA
copy numbers in brain cerebrum (38  13%mtDNA relative to wild-
type brain, P = 0.0002; n = 5; Mann–Whitney U-test), cerebellum
(54  1%, P = 0.0228; n = 4; Mann–Whitney U-test), muscle
(28  12%), and kidney (62  11%) with normal mtDNA levels in
heart and liver (Fig 4C). At age 13 days, untreated Tk2/ animals
A B
Figure 2. dCMP/dTMP effects on brain and spinal cord morphology.
A, B Hematoxylin and eosin stain showing numerous vacuoles in 13-day-old untreated Tk2/ in brain (A) and spinal cord neurons (B). Vacuoles were rare or absent in
Tk2/200dCMP/dTMP and not observed in wild-type mice.
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Figure 3. Complex I immunohistochemistry and complex IV histochemistry of cerebellum.
A–D Complex IV (COX) histochemistry of cerebellum showing deficiency in 13-day-old untreated Tk2/ (A) in contrast to normal COX activity in Tk2+ (B),
Tk2/200dCMP/dTMP (C), and Tk2+200dCMP/dTMP (D) mice.
E–H COX histochemistry (E-F) and immunostaining against COX subunit II (G-H) of cerebellum showed no differences between 29-day-old Tk2/200dCMP/dTMP (upper
panels) and age-matched Tk2+200dCMP/dTMP mice (lower panels).
I–J Anti-complex I NDUFB8 subunit immunostaining of brain showed reduced staining in 29-day-old Tk2/200dCMP/dTMP (I) versus Tk2+200dCMP/dTMP mice (J).
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showed marked mtDNA depletion in brain cerebrum (21  3%,
P < 0.0025; n = 5; Mann–Whitney U-test), muscle (47  1%, P =
0.0303; n = 7; Mann–Whitney U-test), liver (32  1%, P = 0.0140;
n = 5; Mann–Whitney U-test), and kidney (35  9%, P = 0.008;
n = 6; Mann–Whitney U-test), but stable mtDNA depletion in
the cerebellum (Fig 4C). In contrast, with treatment, 13-day-old
Tk2/200dCMP/dTMP mice manifested moderate mtDNA depletion
only in brain cerebrum (66  34%) and normal mtDNA levels in
cerebellum, muscle, heart, liver, and kidney (Fig 4C).
At age 29 days, relative to Tk2+, Tk2/200dCMP/dTMP mice
showed mtDNA depletion that was severe in cerebellum (23  8%)
and brain cerebrum (11  1%) and moderate in muscle
(48  23%), liver (70  13%), and kidney (55  6%) (Fig 4D).
Compared with Tk2/200dCMP/dTMP mice, Tk2/400dCMP/dTMP
animals had less severe mtDNA depletion in brain cerebrum
(22  8%, P = 0.0159; n = 6; Mann–Whitney U-test), but similar
mtDNA depletion in muscle (40  8%), liver (71  36%), and
kidney (43  11%) and cerebellum (26  12%) (Fig 4D).
To assess the impact of treatment on mitochondrial RC enzymes,
their activities and steady-state protein levels in brain cerebrum and
cerebellum were measured. In 13-day-old untreated Tk2/ mice,
relative to untreated wild-type, brain cerebrum showed reduced
A C
B D
Figure 4. dCMP/dTMP effects on dNTP pool balance and mtDNA copy number.
A, B Proportions of dNTPs (in percents) in isolated mitochondria of brain (A) and liver (B) of 13 and 29 postnatal day mice (P13 and P29) demonstrate that levels of dTTP
(red sections) were increased in treated mutant versus untreated mutant mice at P13, but were severely decreased in P29 Tk2/200dCMP/dTMP versus
Tk2+200dCMP/dTMP (*P < 0.05; ***P < 0.0005; Mann–Whitney U-test).
C mtDNA copy numbers in mice reveal rescue of mtDNA depletion in all tissues of treated mutants at P13 (Tk2/ versus Tk2/200dCMP/dTMP; *P < 0.05; **P < 0.005;
***P < 0.0005; Mann–Whitney U-test).
D Dose-related increase in mtDNA copy number in cerebral hemispheres of mutant mice at P29 (expressed as percent of untreated Tk2+ controls; mean  SD;
Tk2/200dCMP/dTMP versus Tk2/400dCMP/dTMP; *P < 0.05; Mann–Whitney U-test) (n = 5 for each group).
Source data is available online for this figure.
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COX activity (57  19%, P = 0.0159; n = 5; Mann–Whitney U-test)
and significantly increased citrate synthase (CS) activity
(148  17%; P = 0.0317; n = 5; Mann–Whitney U-test) (Fig 5A,
Supplementary Table S3) and, when normalized to CS, revealed
decreased activities of complexes I+III (NADH-cytochrome c reduc-
tase) (76  0.06%, P = 0.0159; n = 5; Mann–Whitney U-test) and
II+III (succinate-cytochrome c reductase) (72  9%) in addition to
IV (41  14%, P = 0.0079; n = 5; Mann–Whitney U-test) (Fig 5B,
Supplementary Table S3). The RC defects were more severe in cere-
bellum with significant reductions in all of the complexes when
normalized either to CS (Fig 5C) or to mg-proteins with predomi-
nant defect in complex I (29  15%; P = 0.0087; n = 5; Unpaired
t-test with Welch’s correction) and increased CS activity
(129  34%) (Supplementary Table S4). In contrast, 13-day-old
Tk2/200dCMP/dTMP had normal RC enzyme activities in brain cere-
brum (Fig 5A and B, Supplementary Table S3) and only a mild
defect in complex I (56  21%) in cerebellum compared with age-
matched treated control mice (Fig 5C, Supplementary Table S4). In
29-day-old Tk2/200dCMP/dTMP, activities of RC enzymes were
normal in brain cerebrum (Supplementary Table S3). In contrast,
cerebellum of Tk2/200dCMP/dTMP manifested a mild defect in
complex IV (62  20%) and severe defect in complex I+III
(35  24%, P = 0.0296; n = 5; Mann–Whitney U-test), while RC
activities were completely rescued in the Tk2/400dCMP/dTMP
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Figure 5. dCMP/dTMP efficacy on brain hemisphere and cerebellum biochemistry.
A, B (A) Cerebral hemispheres of untreated Tk2/ mice relative to untreated wild types showed significant increase in CS activity and deficiency of complex IV activity
(micromole/min/mg tissue normalized to mg-protein; mean  SD) as well as (B) defects of complexes IV and I+III activities when referred to CS (mean  SD). In
contrast, with 200 mg/kg/day dCMP/dTMP, activities of citrate synthase and complex IV were normal in cerebrum of 13-day-old Tk2/.
C In cerebellum of mutant mice at ages 13 and 29 days, activities of mitochondrial RC referred to CS (expressed as percent of Tk2+) showed treatment-dose-related
increases.
D–E Western blot of OXPHOS protein (MitoProfile® Total OXPHOS Rodent WB Antibody Cocktail, MitoSciences®) in brain (D) and cerebellum (E) of 13-day-old untreated
Tk2/, 13- and 29-day-old Tk2/200dCMP/dTMP mice, and cerebellum of Tk2/400dCMP/dTMP (expressed as percents relative to Tk2+).
F–H Quantitation of western blot bands demonstrated that treatment normalized levels of complexes I and IV protein in both brain cerebrum and cerebellum tissues at
13 days, but did not correct complexes I and III deficiencies in brain cerebrum and complexes I and IV in cerebellum at 29 days of age. Statistical analyses were
performed using Tk2/ versus Tk2/200dCMP/dTMP with P13 cerebral samples (F); Tk2/200dCMP/dTMP versus Tk2+200dCMP/dTMP with P29 cerebral samples (G); Tk2/
versus Tk2/200dCMP/dTMP with P13 cerebellar samples (H); and Tk2/200dCMP/dTMP versus Tk2/400dCMP/dTMP with P29 cerebellar samples (H) *P < 0.05;
**P < 0.005.
Data information: Statistical analyses were performed with Mann–Whitney U-test and Unpaired t-test with Welch’s correction. CS, citrate synthase; IV, cytochrome c
oxidase (COX); I+III, NADH-cytochrome c reductase; I, NADH-dehydrogenase; II, succinate dehydrogenase; III, cytochrome c reductase; V, ATP synthase; P, postnatal day.
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(Fig 5C, Supplementary Table S4). Western blot analysis of mito-
chondrial RC complex subunits in 13-day-old untreated Tk2/
animals compared with untreated control mice revealed reductions
in steady-state levels of complex I (55  39% brain cerebrum;
38  13% cerebellum, P = 0.025; n = 6; Mann–Whitney U-test) and
complex IV (74  32% brain cerebrum; 44  16% cerebellum,
P = 0.0017; n = 6; Mann–Whitney U-test), while RC protein
levels were normal in 13-day-old Tk2/200dCMP/dTMP mice
(Fig 5D–F and H). In 29-day-old Tk2/200dCMP/dTMP compared with
Tk2+200dCMP/dTMP, we observed reduced levels of subunits of
complexes I (45%  2, P = 0.0196; n = 4; Mann–Whitney U-test)
and III (69%  2) in brain cerebrum (Fig 5G) and complexes I
(34%  4) and IV (49%  1, P = 0.0267; n = 4; Unpaired t-test
with Welch correction) in cerebellum (Fig 5H). In 29-day-old
Tk2/400dCMP/dTMP, we observed complete rescue of the RC defect
when compared to Tk2+400dCMP/dTMP.
Deoxynucleotide metabolism
To understand the metabolism of dCMP/dTMP after oral gavage
administration, we measured levels of dCMP/dTMP and their
metabolites in muscle and liver tissues and in plasma after 30 min
of oral gavage. In Tk2/200dCMP/dTMP mice, deoxynucleoside mono-
phosphates were not detectable. Levels of deoxyuridine and deoxy-
thymidine were markedly increased at age 13 days, but
subsequently lower in 29-day-old mice (Fig 6A–C). Thymidine phos-
phorylase (TP) degrades deoxyuridine and deoxythymidine, respec-
tively, to uracil and thymine plus deoxyribose 1-phosphate (Brown
& Bicknell, 1998; Hirano et al, 2004). To understand the cause for
differences in deoxyuridine and deoxythymidine plasma levels
between 13 and 29 days of age, we measured the activity level of
TP in small intestine, brain, and liver. TP activity was higher in the
small intestine at P29 (Fig 6D), but unchanged in brain and liver
tissues (Supplementary Table S5). Therefore, intestinal TP is
responsible for the rapid catabolism of deoxyuridine and deoxyt-
hymidine at P29 and the resulting reduced plasma levels.
Tk2 activity was confirmed to be normal in treated and untreated
Tk2+ mice and reduced in Tk2/ mice in muscle and brain. Unex-
pectedly, Tk1 activity was increased in brain and muscle of 13- and
29-day-old treated mice (Fig 6E and F).
Discussion
Mitochondrial DNA depletion syndrome (MDS) is a frequent cause
of severe childhood encephalomyopathy characterized molecularly
by reduction of mtDNA copy number in tissues and insufficient
synthesis of mitochondrial RC complexes (Hirano et al, 2001;
Spinazzola & Zeviani, 2009). Mutations in eight nuclear genes have
been identified as causes of infantile MDS (TK2, DGUOK, POLG,
MPV17, RRM2B, SUCLA2, SUCLG1, and C10orf2) (Mandel et al,
2001; Saada et al, 2003; Naviaux & Nguyen, 2004; Elpeleg et al,
2005; Spinazzola et al, 2006; Bourdon et al, 2007; Ostergaard et al,
2007; Sarzi et al, 2007); 7 of the genes encode proteins involved in
mtDNA replication or in the metabolism of deoxynucleotide triphos-
phate pools utilized as precursors for DNA replication (Copeland,
2012).
Treatment for MDS, like most mitochondrial disorders, has been
limited to supportive therapies; however, understanding the
pathomechanism of MDS enables the design of treatment strategies
targeting either the cause of the disease or the downstream meta-
bolic defects. Enzyme replacement by allogenic hematopoietic stem
cell transplantation (HSCT) has shown promising initial results with
MNGIE due to mutations in the TYMP gene encoding thymidine
phosphorylase, another enzyme involved in nucleoside metabolism
(Nishino et al, 1999; Hirano et al, 2006; Garone et al, 2011) but
limited to disorders with toxic metabolites that can be eliminated by
circulating cells. In contrast to AHSCT, gene therapy holds greater
promise for mitochondrial diseases and other genetic disorders, but
faces several barriers such as inefficient gene delivery, immune
responses, and short-lived effects.
An alternative metabolic bypass approach has been tested in
mtDNA-depleted myotubes from patients with DGUOK mutations.
Remarkably, supplementation of culture media with deoxypurine
nucleoside monophosphates (dAMP and dGMP), the products of
dGK activity, partially restored mtDNA levels (Bulst et al, 2009)
indicating that extracellular dAMP and dGMP are able to cross
plasma and mitochondrial membranes and reach the mitochondrial
matrix where they enter the nucleotide salvage pathway after
bypassing the dGK defect. Concentrations of dAMP/dGMP up to
200–400 lM increased mtDNA levels in a dose-related fashion,
while higher levels up to 1,200 lM (corresponding to 150 mg/kg/
day in mice) did not further increase mtDNA or cause nuclear DNA
or mtDNA qualitative defects such as chromosomal rearrangement
or mtDNA deletions (Bulst et al, 2009).
We tested dCMP and dTMP supplementation in our Tk2 knock-in
mouse model to bypass the Tk2 defect. Deoxypyrimidine nucleoside
monophosphate supplementation delayed the disease onset,
reduced the severity of phenotypic manifestations, and prolonged
the survival of the mutant mice in a dose-related manner. No
adverse side effects, including malignancies, were observed. Oral
dTMP/dCMP crossed biological barriers including the blood–brain
barrier (BBB) because treatment increased dTTP in brain and liver
in 13-day-old Tk2/ mice and augmented levels of mtDNA restor-
ing the mitochondrial RC activities and protein defects in brain,
heart, muscle, liver, and kidney of 13- and 29-day-old mutant mice.
Figure 6. Metabolism of dCMP/dTMP.
A–C Level of deoxyuridine and deoxythymidine in liver, brain, and muscle tissues was markedly higher at 13 days, but lower at 29 days. Deoxynucleoside levels are
expressed as percents relative to age-matched untreated wild-type controls (mean  SD) (Tk2/200dCMP/dTMP, Tk2+200dCMP/dTMP, Tk2/400dCMP/dTMP, and
Tk2+400dCMP/dTMP versus untreated Tk2+; *P < 0.05;**P < 0.005; Unpaired t-test with Welch’s correction; n > 3 mice for each group).
D Thymidine phosphorylase (TP) activity in small intestine of treated and untreated Tk2 mice showing dramatically increased activity at age 29 days relative to
13 days. Data expressed as nmol/h/mg-proteins (mean  SD).
E, F Tk1 and Tk2 activities in brain and muscle tissues of treated and untreated mice showing increased Tk1 activity in treated mice. Data expressed in pmol/min/mg-
proteins (mean  SD) (Tk2+/+ versus Tk2+/+200dCMP/dTMP; Tk2+/ versus Tk2+/200dCMP/dTMP; Tk2/ versus Tk2/200dCMP/dTMP; *P < 0.05; Unpaired t-test with
Welch’s correction; n > 3 mice for each group). P = p-value.
▸
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Treatment-related marked improvements of mtDNA levels and
biochemical defects in muscle, which is the most affected tissue in
TK2 mutant patients, suggest that dCMP/dTMP might be more effi-
cacious in patients with myopathy due to TK2 deficiency than in
Tk2/ mice with severe CNS involvement.
Analyses of plasma and tissue levels of dCMP/dTMP and their
metabolites revealed increases in deoxythymidine (dT) and deoxy-
uridine (dU), but not dCMP or dTMP 30 min after oral gavage treat-
ment. Based on these findings, we hypothesize that dCMP/dTMP
can be effective either by rapid and transient bypassing of the
enzyme defect and/or by increasing the dT and thymine (T)
substrates as documented by measurements of dT/T levels in
plasma and tissue and by dNTP pool analysis in 13-day-old mice. In
contrast, dCMP is catabolized by deoxycytidine deaminase, the
enzyme responsible for dCMP conversion to deoxyuridine mono-
phosphate (dUMP) (Heinemann & Plunkett, 1989; Jansen et al,
2011). The dUMP may be converted to dTMP via thymidylate
synthase and may contribute to the observed increases in dTTP
levels (Fig 7). Because nucleosides are intrinsically unstable, catab-
olized in vascular and tissue compartments, and ineffectively phos-
phorylated by mutant TK2, we postulate that treatment with dT and
dC may be less effective than dTMP and dCMP in Tk2 mutant mice.
We previously demonstrated that Tk2 (mitochondrial) activity is
constant in the second week of life, whereas cytosolic Tk1 activity
decreases significantly between postnatal day 8 and 13 (Dorado
et al, 2011). The downregulation of Tk1 activity unmasks Tk2 defi-
ciency in Tk2/ mice and coincides with the onset of mtDNA
depletion causing inexorable organ failure leading to death. In the
present work, we demonstrated that oral dCMP and dTMP delayed
the reduction in Tk1 activity. Thus, in addition to providing
substrates for dNTP synthesis, dCMP/dTMP supplementation in
Tk2/ mice appears to enhance compensatory Tk1 activity. Nucle-
otides generated by de novo synthesis can enter into mitochondria
through carriers that have been previously demonstrated indirectly
in the case of dTMP or directly by PNC1 in the case of dTTP
(Ferraro et al, 2006; Franzolin et al, 2012). Once in mitochondria,
dTMP and dTTP can be incorporated into replicating mtDNA as
demonstrated directly through in vitro modulation of Tk1 activity
and PNC1 carrier in cells exposed to radiolabeled thymidine (Franz-
olin et al, 2012) and indirectly by our in vivo results. The reduced
efficacy of dCMP/dTMP after age 29 days may be due to decreased
Tk1 activity.
Oral dCMP/dTMP failed to improve dCTP and dTTP levels in
brain cytoplasm and mitochondria of 29-day-old mutants that mani-
fested a head tremor, growth plateau, and subsequently died. The
head tremor is likely due to cerebellar dysfunction as we noted a
severe complex I protein defect in this tissue. The inability of
dCMP/dTMP to prevent CNS manifestations is likely attributable to
the development of the blood–brain barrier in Tk2/ mice after age
13 days. Therefore, intrathecal treatment may be required in the
Tk2/ mice and TK2 patients with encephalopathy (Galbiati et al,
2006; Gotz et al, 2008).
There are several additional factors that contribute to the incom-
plete efficacy of dCMP/dTMP therapy in the Tk2-deficient mice.
First, orally administered dTMP is catabolized by the dramatically
increased thymidine phosphorylase activity in the small intestine of
A
B
Figure 7. Deoxypyrimidine monophosphates pathways.
Graphical summary of the pathways modulated by oral gavage dCMP/dTMP treatment.
A dTMP metabolism. dTMP treatment may enter as monophosphate into the mitochondria bypassing the TK2 enzymatic defect as demonstrated by the increased level
of dTTP in postnatal day 13 mutant mouse tissues. However, dTMP is also rapidly degraded by 50-nucleotidase in the small intestine to the nucleoside (dT), which
may be processed via three different pathways: (i) phosphorylated by residual Tk2 activity to eventually produce dTTP within mitochondria; (ii) converted to dTMP by
cytosolic Tk1; or (iii) catabolized by thymidine phosphorylase (TP). The combination of reduced Tk1 activity in brain and increased thymidine phosphorylase (TP)
activity in small intestine after postnatal day 13 may account for the reduced efficacy of the treatment in rescuing the dNTP pool balance after age 13 days.
B dCMP metabolism. dCMP/dTMP treatment did not increase dCTP levels in mitochondria of Tk2/ mice suggesting that dCMP administered orally does not enter into
mitochondria. Instead, dCMP degraded to nucleoside (dC) may be a source of dTMP as shown in the figure or may be catabolized to uracil by cytosolic TP.
ª 2014 The Authors EMBO Molecular Medicine Vol 6 | No 8 | 2014
Caterina Garone et al Bypass therapy for Tk2 deficiency EMBO Molecular Medicine
1023
29-day-old mice. Second, supplemental dTMP and dCMP failed to
fully correct intra-mitochondrial levels of dTTP and dCTP, indicat-
ing that mitochondrial membranes impede dNTP entry; this hypoth-
esis is supported by the low intra-mitochondrial dCTP/dTTP levels
with normal cytosolic concentrations of dCTP and dTTP in liver of
29-day-old treated mice. Third, the doses of dTMP/dCMP may have
been insufficient, as we have observed dose-related efficacy.
Addressing these therapeutic obstacles (e.g. inhibiting TP activity)
may lead to enhance effectiveness of dCMP/dTMP treatment in
Tk2/ mice.
In conclusion, deoxypyrimidine supplementation for Tk2 defi-
ciency is the first effective and safe in vivo treatment option that
may be readily translated to patient affected by Tk2 mutations.
Furthermore, this approach is potentially applicable to individuals
with other mitochondrial disorders due to nucleotide pools unbal-
ance.
Materials and Methods
Mice
Generation and characterization of Tk2 H126N knock-in mice were
previously reported (Akman et al, 2008). All experiments were
performed according to a protocol approved by the Institutional
Animal Care and Use Committee of the Columbia University Medical
Center and were consistent with the National Institutes of Health
Guide for the Care and Use of Laboratory Animals. Mice were
housed and bred according to international standard conditions,
with a 12-h light, 12-h dark cycle, and sacrificed at 4, 13, and
29 days of age.
Organs (brain, spinal cord, liver, heart, kidney, quadriceps
muscle, lung, and gastrointestinal tract) were removed and either
frozen in the liquid phase of isopentane, pre-cooled near its freezing
point (160°C) with dry ice or fixed in 10% neutral-buffered forma-
lin and embedded in paraffin using standard procedures. Paraffin-
embedded tissue were then stained with hematoxylin and eosin
(H&E) for morphological study or processed for immunostaining
studies with GFAP, COX I, or complex I subunit as described in
detail in the supplemental procedures. All the experiments were
performed in at least three mice per group. Both heterozygous and
homozygous wild-type mice were considered as control group
(Tk2+) as no clinical and biochemical difference were previously
described (Akman et al, 2008; Dorado et al, 2011).
Treatment administration and experimental plan
Deoxycytidine monophosphate (dCMP) and deoxythymidine mono-
phosphate (dTMP) (Hongene Biotech, Inc.) were administered in
50 ll of Esbilac milk formula for small pets (Pet-Ag) by daily oral
gavage to Tk2 H126N knock-in mice (Tk2/) and aged-matched
control wild type (Tk2+) using 2 doses, 200 and 400 mg/kg/day,
from postnatal day 4 to day 29. At age 29 days, mice were separated
from the mother and the treatment was continued by administration
of dCMP and dTMP in drinking water using equimolar doses,
respectively, of 1.6 and 3.2 mM. A negative control group of
untreated Tk2 mutant and control wild-type mice were weighted
and observed closely for comparison.
Phenotype assessment
To define the degree of safety and efficacy of dTMP/dCMP, we
compared survival time, age at onset of disease, type and severity of
symptoms, occurrence of side effects, and proportion of treatment
termination due to adverse events in treated and untreated Tk2
mice. General behavior, survival time, and body weights of the mice
were assessed daily beginning at postnatal day 4. Videotaping and
open-field test with an Opto-Varimetrix-3 sensor system (Columbus
Instruments) were performed at 13 and 29 days by counting hori-
zontal and vertical movements, by recording ambulatory and resting
time and by measuring the total distance traveled in 10 min.
Brain histology
Brain and spinal cord samples from 13- to 29-day-old mice were
fixed with 10% neutral-buffered formalin and embedded in paraffin
using standard procedures. Cerebellum, brainstem, hippocampus,
cerebral cortex, and cervical, thoracic and lumbar tracts of the
spinal cord were analyzed.
Sections (5 lm thick) were stained with H&E and luxol fast blue
to analyze the overall structure of the tissue. Immunostaining with
antibodies against GFAP, complex I (NDUFB6), or COX subunit 2
was also performed. Briefly, paraffin-embedded brain and spinal
cord slides were deparaffinized, rehydrated, and rinsed in phos-
phate-buffered saline solution (PBS). To block endogenous peroxi-
dase activity, sections were incubated with 3% hydrogen peroxide
in methanol. Slides were then placed in 0.1 M sodium citrate buffer
(pH 6.0) and heated in a microwave oven for 15 min, for antigen
retrieval. Slides were incubated with mouse anti-GFAP antibody
(1:100) (Novocastra. NCL-GFAP-GA5) or mouse monoclonal anti-
body anti-complex I 17 kDa (NDUFB6) subunit (1:100) (A21359;
Molecular Probes) or mouse monoclonal antibody anti-COX subunit
2 (1:100) (clone COX 229, A6404; Molecular Probes) overnight at
4°C. Sections were subsequently rinsed in PBS and incubated with
anti-mouse M.O.M. Peroxidase kit, 1:200 dilution for 60 min at
room temperature. Immunoreactivity was detected by avidin–biotin
complex (ABC) with DAB substrate (Vector Laboratories, Burlin-
game, CA, USA). Slides were examined by light microscopy using
an Olympus BX51 microscope, and images were captured with a
QImaging Retiga EXi digital camera, using QCapture software
version 2.68.6.
dNTP pool by polymerase extension essay
Tissues were homogenized on ice in 10 volumes (w/v) of cold
MTSE buffer (210 mM mannitol, 70 mM sucrose, 10 mM Tris–HCl
pH 7.5, 0.2 mM EGTA, 0.5% BSA) and centrifuged at 1,000 g for
5 min at 4°C, followed by three centrifugations at 13,000 g for
2 min at 4°C. Supernatant was precipitated with 60% methanol for
the mitochondrial fraction and 100% methanol for the cytosolic
fraction, kept 2 h at 80°C, boiled 3 min, stored at 80°C (from 1 h
to overnight), and centrifuged at 20,800 g for 10 min at 4°C. Super-
natants were evaporated until dry, and pellet was resuspended in
65 ll of water and stored at 80°C until analyzed. To minimize
ribonucleotide interference, total dNTP pools were determined as
reported (Ferraro et al, 2010; Marti et al, 2012a). Briefly, 20 ll
volume reactions was generated by mixing 5 ll of sample or
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standard with 15 ll of reaction buffer [0.025 U/ml ThermoSequen-
ase DNA polymerase (GE Healthcare, Piscataway, NJ, USA) or
Taq polymerase (Life Technologies, NY, USA), 0.75 lM 3H-dTTP or
3H-dATP (Moravek Biochemicals), 0.25 lM specific oligonucleotide,
40 mM Tris–HCl, pH 7.5, 10 mM MgCl2, 5 mM DTT]. After 60 min
at 48°C, 18 ml of reaction were spotted on Whatman DE81 filters,
air dried, and washed three times for 10 min with 5% Na2HPO4,
once in distilled water and once in absolute ethanol. The retained
radioactivity was determined by scintillation counting.
Nucleotides measurements by HPLC
Nucleotides concentrations were measured as described (Akman
et al, 2008) with minor modifications in brain, muscle, and liver.
50 mg of tissue was homogenized in 500 ml of ice-cold 0.5 M
perchloric acid and centrifuge at 16,000 × g for 10 min at 4°C. The
pellets were stored at 80°C for protein measurement, and nucleo-
tides were measured in the resultant supernatant using the Alliance
HPLC (Waters Corporation, Milford, MA, USA) with an Alltima
C18NUC reverse-phase column (Alltech Associates, Deerfield, IL,
USA) and UV detection. After stabilizing the column with the mobile
phase, samples (50 ml) were injected onto the HPLC system. The
mobile phase consists of 0.2 M ammonium phosphate buffer pH 3.5
(phase A) and 30% methanol in 0.2 M ammonium phosphate
buffer, pH 3.5 (phase B). The time schedule for the binary gradient
was as previously reported (Ferraro et al, 2006). Standard curves
for dCTP, dTTP, dTMP, and dCMP were constructed with 15, 30,
and 60 mM of each nucleotide. Absorbance of the samples was
measured with an UV detector at 260 nm wavelength, and the
concentration of each nucleotide in the samples was calculated
based on the peak area. Nucleotide levels were expressed in nmol/
mg prot.
Nucleosides measurements by HPLC
Deoxythymidine (dT), deoxyuridine (dU), uracile (U), and thymine
(T) levels were assessed by a gradient-elution HPLC method as
described previously (Lopez et al, 2009; Marti et al, 2012b), with
minor modifications. Briefly, deproteinized samples were injected
into an Alliance HPLC system (Waters Corporation) with an Alltima
C18NUC reversed-phase column (Alltech) at a constant flow rate of
1.5 ml/min (except where indicated) using three buffers: eluent A
(20 mM potassium phosphate, pH 5.6), eluent B (water), and eluent
C (methanol). Samples were eluted over 60 min with a gradient as
follows: 0–5 min, 100% eluent A; 5–25 min, 100–71% eluent A,
29% eluent B; 25–26 min, 0–100% eluent C; 26–30 min, 100%
eluent C; 30–31 min, 0–100% eluent B; 31–35 min, 100% eluent B
(1.5 – 2 ml/min); 35 – 45 min, 100% eluent B (2 ml/min); 45 –
46 min, 100% eluent B (2–1.5 ml/min); 46–47 min, 0–100% eluent
C; 47–50 min, 100% eluent C; 50–51 min, 0–100% eluent A; and
51–60 min, 100% eluent A.
Absorbance of the elutes was monitored at 267 nm, and dThd
and dUrd peaks were quantified by comparing their peak areas with
a calibration curve obtained with aqueous standards. For definitive
identification of dT, dU, U, and, T peaks for each sample, we used a
second aliquot treated with excess of purified E. coli TP (Sigma) to
specifically eliminate dT and dU. The detection limit of this method
is 0.05 mmol/l for all nucleosides.
RT-qPCR: mitochondrial DNA quantification
Real-time PCR was performed with the primers and probes for
murine COX I gene (mtDNA) and mouse glyceraldehyde-3-
phosphate dehydrogenase (GAPDH, nDNA) (Applied Biosystems,
Invitrogen, Foster City, CA, USA) as described using standard curve
quantification, in an ABI PRISM 7,000 Sequence Detection System
(Applied Biosystems) (Dorado et al, 2011). MtDNA values were
normalized to nDNA values and expressed as percent relative to
wild type (100%).
Mitochondrial respiratory chain protein levels
Thirty micrograms of whole brain cerebrum or cerebellum extracts
was electrophoresed in an SDS-12% PAGE gel, transferred to
Immun-BlotTM PVDF membranes (Bio-Rad, Hercules, CA, USA) and
probed with MitoProfile Total OXPHOS Rodent WB Antibody Cock-
tail of antibodies (MitoSciences, Eugene, OR, USA). Protein–anti-
body interaction was detected with peroxidase-conjugated mouse
anti-mouse IgG antibody (Sigma-Aldrich, St Louis, MO, USA), using
AmershamTM ECL Plus western blotting detection system (GE
Healthcare Life Sciences, UK). Quantification of proteins was carried
out using NIH ImageJ 1.37V software. Average gray value was
calculated within selected areas as the sum of the gray values of all
the pixels in the selection divided by the number of pixels.
Mitochondrial respiratory chain enzyme activities by
spectrophotometer analysis
Mitochondrial RC enzymes analysis was performed in cerebrum and
cerebellum tissues as previously described (DiMauro et al, 1987).
Nucleosides and nucleotides metabolic enzymes
Thymidine phosphorylase and thymidine kinase 1 and 2 activities
were measured as previously described (Martı´ et al, 2003; Lopez
et al, 2009; Dorado et al, 2011).
Statistical methods
Data are expressed as the mean  SD of at least three experiments
per group. Gehan-Breslow-Wilcoxon test was used to compare the
survival proportion of each group of mice. Unpaired t-test with
Welch’s correction and Mann–Whitney U-test were used to compare
13-day-old Tk2+ versus untreated Tk2/, 13-day-old untreated
Tk2/ versus Tk2/200dCMP/dTMP, 29-day-old wild-type versus
Tk2/200dCMP/dTMP and Tk2/400dCMP/dTMP, for molecular and
biochemical studies. Response to treatment was evaluated
comparing Tk2/ versus Tk2/200dCMP/dTMP at 13 days and
Tk2/200dCMP/dTMP versus Tk2/400dCMP/dTMP. A P-value of < 0.05
was considered to be statistically significant.
Supplementary information for this article is available online:
http://embomolmed.embopress.org
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